The aim of this study, therefore, was to assess whether there was any molecular link between MAD2, TLR4 and MyD88 in ovarian cancer and to further explore the mechanisms each of these biomarkers utilise, in order to render ovarian cancer cells resistant to paclitaxel therapy. Here, MAD2L1 is linked to ovarian cancer.